Joseph Douglas Lyon, Chief Accounting and Technology Officer of Corcept Therapeutics Inc (NASDAQ:CORT), filed a Form 4 on September 16, 2026, reporting stock option exercises and open-market share sales that took place on September 14, 2026 pursuant to a previously adopted 10b5-1 plan.
Key Highlights
- Option exercise - first tranche: Lyon exercised 2,596 stock options at an exercise price of $11.35 per share, expiring February 8, 2029.
- Option exercise - second tranche: Lyon exercised 7,404 stock options at an exercise price of $13.56 per share, expiring February 7, 2030.
- Sale - first tranche: 7,812 shares of common stock were sold at a weighted average price of $113.3206 per share, with actual prices ranging from $112.81 to $113.72.
- Sale - second tranche: 2,188 shares of common stock were sold at a weighted average price of $114.1163 per share, with actual prices ranging from $113.92 to $114.50.
- Remaining direct ownership: Following all transactions, Lyon directly holds 5,683 shares of common stock, according to the filing.
- 10b5-1 plan: The sales were made pursuant to a plan adopted by Lyon on June 10, 2026.
Lyon Exercises Options and Sells Shares in Corcept Therapeutics
According to the Form 4 filed with the SEC, Joseph Douglas Lyon, identified in the filing as Chief Accounting and Technology Officer of Corcept Therapeutics Inc, carried out four transactions on September 14, 2026. Two transactions involved the exercise of fully exercisable stock options using transaction code "M," and two involved open-market sales using transaction code "S." Both sales were executed under a Rule 10b5-1(c) plan the reporting person adopted on June 10, 2026, as indicated by the checked box on the form.
The first option exercise converted 2,596 options, priced at $11.35, into an equivalent number of common shares, leaving no remaining options in that grant. The second exercise converted 7,404 options priced at $13.56, with 4,167 options from that grant remaining after the transaction. Immediately following both exercises, Lyon held 15,683 shares directly. The subsequent sales of 7,812 shares and 2,188 shares reduced his directly held position to 5,683 shares, the filing states.
The filing notes that Lyon's beneficial ownership figure includes shares underlying several unvested restricted stock awards: 178 shares from a December 1, 2025 grant, 398 shares from a March 2, 2026 grant, 537 shares from a June 1, 2026 grant, and 130 shares from a September 1, 2026 grant. The filing states that 100% of those restricted stock awards will vest on the one-year anniversary of each grant date, provided the reporting person satisfies certain requirements.
What Was Disclosed
The Form 4 discloses stock option exercises and share sales by Corcept Therapeutics' Chief Accounting and Technology Officer on September 14, 2026. Total shares sold numbered 10,000, at weighted average prices of $113.3206 and $114.1163, under an established 10b5-1 plan.



Please wait processing your request...